Join Now!

Begin our membership application process today!

Contact Us                                                                                                        

Kena Norris
Executive Director

312.227.7406
knorris@ccpapp.org

Priya Stemler
Director of Operations

312.227.7437
pstemler@ccpapp.org

Paresh Patel
National Sales Manager

312.227.7436
papatel@ccpapp.org

Jennifer Jackson
Sr. Administrative Assistant
312.227.7442
jdjackson@ccpapp.org
 
Sonia Perez Gandara
Member Relations Specialist

312.227.7508
sgandara@ccpapp.org

General Inquiries:
312.227.7444
info@ccpapp.org
 
 

DTaP-IPV Vaccine for Your 4- to 6-Year-Old Patients (July 2018)

Quadracel_Back_to_School_Pic

As a reminder, members of CCPA Purchasing Partners are eligible for special pricing on Sanofi Pasteur's Quadracel vaccine. As many of our member practices are preparing for back-to-school visits, please consider the benefits of Quadracel vaccine for both your insured and VFC-eligible patients

Presentation: Quadracel vaccine is available as a 10-dose package, vial presentation (National Drug Code number 49281-0562-10).

Indication: A single dose of Quadracel vaccine is approved for use in children 4 through 6 years of age as a fifth dose in the diphtheria, tetanus, pertussis vaccination (DTaP) series, and as a fourth or fifth dose in the inactivated poliovirus vaccination (IPV) series, in children who have received 4 doses of Pentacel® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate [Tetanus Toxoid Conjugate] Vaccine) and/or DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed).

Additional Information: Quadracel vaccine is a Sanofi Pasteur product and, when used with Pentacel vaccine, provides continuity of using the same antigens throughout the DTaP, IPV, and Hiba vaccination series.

As a reminder, combination vaccines are encouraged, as they potentially: 

  • Reduce the number of vaccine injections
  • Help remove barriers to timely immunization
  • Help with vaccinating children in line with current CDC recommendations
  • Simplify your immunization schedule

a Hib = Haemophilus influenzae type b.

IMPORTANT SAFETY INFORMATION FOR PENTACEL AND QUADRACEL VACCINES

Contraindications to vaccination with Pentacel or Quadracel vaccine include: a severe allergic reaction (eg, anaphylaxis) to any ingredient of the vaccine, or following any other diphtheria toxoid-, tetanus toxoid-, pertussis antigen-containing vaccine, inactivated poliovirus vaccine, or Haemophilus influenzae type b vaccine (Pentacel vaccine only); encephalopathy within 7 days after a previous dose of a pertussis antigen-containing vaccine with no other identifiable cause; or a progressive neurologic disorder.

Carefully consider benefits and risks before administering Pentacel or Quadracel vaccine to persons with a history of: fever ≥105°F, hypotonic-hyporesponsive episode (HHE), or persistent, inconsolable crying lasting ≥3 hours within 48 hours after a previous pertussis antigen-containing vaccine; seizures within 3 days after a previous pertussis antigen-containing vaccine; Guillain-Barré syndrome occurring within 6 weeks following receipt of a prior vaccine containing tetanus toxoid; or adverse events after a previous dose of Pentacel or Quadracel vaccine or receipt of any other tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine.

For infants and children with a history of previous seizures, an antipyretic may be administered (in the dosage recommended in its prescribing information) at the time of vaccination with Pentacel vaccine and for the next 24 hours.

Apnea following intramuscular vaccination has been observed in some infants born prematurely.

The most common local and systemic adverse reactions to Pentacel vaccine include erythema, swelling, and tenderness at the injection site; fever, fussiness, and abnormal crying. The most common local and systemic adverse reactions to Quadracel vaccine include pain, erythema, and edema at the injection site; myalgia, malaise, and headache. Other adverse reactions may occur.

Vaccination with Pentacel or Quadracel vaccine may not protect all individuals.

INDICATION FOR PENTACEL AND QUADRACEL VACCINES

Pentacel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to H influenzae type b. Pentacel vaccine is approved for use as a 4-dose series in children 6 weeks through 4 years of age (prior to fifth birthday).

Quadracel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis. A single dose of Quadracel vaccine is approved for use in children 4 through 6 years of age as a fifth dose in the diphtheria, tetanus, pertussis vaccination (DTaP) series, and as a fourth or fifth dose in the inactivated poliovirus vaccination (IPV) series, in children who have received 4 doses of Pentacel vaccine and/or DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed).

Before administration, please see the full Prescribing Information for Pentacel or Quadracel vaccines.

For questions regarding the above referenced vaccine products, please contact your respective Sanofi Pasteur vaccine representative or please call Sanofi Pasteur at 1.800.VACCINE (1.800.822.2463).
 
Feel free to contact CCPAPP with any questions regarding pricing and/or your participation in our Vaccine Discounts Program. If you are not yet a member of CCPAPP, please visit the Join section of our website to enroll today!
 

Quadracel_Picheader_logo_sp[1]

 
 

« Back

 
 

 

 

logo_Merck[1]

header_logo_sp[1]

 

 

LOGO_MMS

 

 

 

 
Copyright © 2021 CCPA Purchasing Partners. All rights reserved.
Web site design and development by Americaneagle.com